Kolltan Pharmaceuticals
Developing novel biologic drugs targeting receptor tyrosine kinases (RTKs) for oncology and immunology.
Launch date
Employees
Market cap
-
Enterprise valuation
€214m (Public information from Nov 2016)
New Haven Connecticut (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $6.0m | Early VC | |
$25.0m | Series C | ||
| N/A | $60.0m | Series D | |
N/A | Spinout | ||
$235m Valuation: $235m | Acquisition | ||
| Total Funding | €133m | ||
Related Content
Recent News about Kolltan Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.